Skip to content
Catalyst

PapersPMID:41342306

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

The Cochrane database of systematic reviews2025The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, very limited evidenceno difference foundSerious adverse event incidence
  2. Finding, very limited evidenceno difference foundHealth-related quality of life
Study, every finding
meta-analysis

No finding here moved its endpoint.

  • “Methylphenidate may not affect serious adverse events (risk ratio (RR) 0.80, 95% CI 0.39 to 1.67; I² = 0%; 26 trials, 3673 participants; very low-certainty evidence).”
    Participants
    3,673
    Effect
    0.8 risk ratio, 95% CI 0.39 to 1.67
    Population
    children and adolescents with ADHD; primary outcome (serious adverse events)
  • “Methylphenidate may improve teacher-rated general behaviour versus placebo (SMD -0.62, 95% CI -0.91 to -0.33; I² = 68%; 7 trials 792 participants; very low-certainty evidence), but may not affect quality of life (SMD 0.40, 95% CI -0.03 to 0.83; I² = 81%; 4 trials, 608 participants; very low-certainty evidence).”
    Participants
    608
    Effect
    0.4 standardised mean difference, 95% CI −0.03 to 0.83
    Population
    children and adolescents with ADHD; secondary outcome (quality of life), instrument not named by the review

Study record

Design
meta-analysis
Species
human
Population
children and adolescents (aged 3-21, mean 9.8 years) with ADHD; 212 randomised trials (16,302 participants randomised, 165 trials with usable data on 14,271 participants)
Participants
16,302
Comparator
not stated in the paper / placebo
Duration
not reported
Endpoints measured
5